Using mesenchymal stromal cells in islet transplantation by Arzouni, Ahmed Ali et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Arzouni, A. A., Vargas-Seymour, A., King, A., Nardi, N., & Jones, P. M. (2018). Using mesenchymal stromal
cells in islet transplantation. Stem cells translational medicine.
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 13. Apr. 2018
Using mesenchymal stromal cells in islet transplantation  
 
Ahmed A Arzouni, Andreia Vargas-Seymour, Nance Nardi1, Aileen JF King and Peter M Jones2 
 
Department of Diabetes, School of Life Course Sciences, Faculty of Life Sciences and Medicine, 
King’s College London, Guy’s Campus, London SE1 1UL, UK. 
 
1Laboratory of Stem Cells and Tissue Engineering, Universidade Luterana do Brasil, Brazil 
 
2Corresponding author 
 
Peter M Jones 
Department of Diabetes  
School of Life Course Sciences 
Faculty of Life Sciences and Medicine 
King’s College London 
Guy’s Campus, Hodgkin Building (HB2.10N) 
London SE1 1UL 
 UK 
 
peter.jones@kcl.ac.uk 
+44(0)2078486273 
 
Keywords 
Mesenchymal stromal cell; islet transplantation; Type 1 diabetes; extracellular matrix; immunoregulation 
  
  
 Introduction  
Islet transplantation and Type 1 diabetes 
Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease characterised by 
hyperglycemia caused by insulin deficiency due to the selective destruction of β-cells within 
pancreatic islets of Langerhans. People with T1DM are dependent on the administration of 
exogenous insulin to survive, either by (multiple) daily injection or infusion. However, 
sporadic administration of exogenous insulin often fails to maintain tight glycaemic control, 
such that hyperglycemic and hypoglycemic excursions are common, both of which are 
associated with devastating side effects1,2. β-cell replacement offers the potential for 
providing physiological glycemic control, so avoiding hyperglycemic and hypoglycemic 
episodes. Whole pancreas transplantation is surgically invasive and associated with significant 
co-morbidity3 whereas transplantation of the endocrine islets, which comprise only 2-3 % of 
the total pancreas, is a safe procedure with little or no co-morbidity4. Transplantation of 
isolated islets as a therapy for T1DM is therefore an attractive therapeutic option. 
 
The UK islet Transplant Consortium (UKITC) was established in 2000 and the UK National 
Health Service established the first government-funded islet transplant service focused on 
people with T1DM with severe hypoglycemia unawareness. Worldwide, over 1,500 people 
with T1DM have now received intraportal islet transplantation in 40 centres 
(https://citregistry.org/content/citr-9th-annual-report). Islet transplantation outcomes have 
improved year-on-year5,6, with recent reports that approximately 50 % of graft recipients 
remain insulin independent at 5 years and more, which places the success rate of islet 
transplantation on par with that of whole  pancreas transplantation7.  
 Current issues with islet transplantation   
The availability of islet transplantation as a therapeutic option to a wider population of people 
with T1D is severely limited by a shortage of tissue donors. Current isolation techniques 
recover only around half of the islets from a pancreas, so a single transplantation requires 
multiple donors. The scarcity of donor islets is exacerbated by the loss of functional islets 
during the islet isolation and pre-implantation culture period due to ischemia, physical and 
oxidative stresses and the deleterious effects of inflammatory cytokines. Culturing human 
islets for 24-72 h prior to transplantation has been adopted by most islet transplant centres. 
This allows for the initiation of time-dependent immunosuppressive regimens in the graft 
recipient and enables quality control testing of the donor islets and their shipment to distant 
transplantation centres. However, maintaining islet viability after isolation remains 
challenging. It is well documented that islets deteriorate rapidly during culture8,9, with 
reported average losses of 20 % of the islet cell mass after 20 h, and occasional losses of > 50 
% of the islet cell mass resulting in the cancellation of the planned transplantation 
procedure10. There is also convincing evidence that a substantial proportion of the functional 
islet graft (up to 80 %) is lost in the immediate post-transplantation period (24-48 h), because 
of deleterious responses of transplanted islet cells to a hypoxic, inflammatory, immunogenic 
host environment11. Strategies which improve the functional survival of islets both before and 
after transplantation will improve the outcome of individual grafts, and also enable the 
limited pool of donor islets to treat many more people with T1DM by avoiding the current 
clinical practice of administering multiple grafts to achieve normoglycemia5. Genetic 
manipulation strategies have been reported to improve the survival and/or function of 
transplanted islets12, but this is unlikely to be acceptable in clinical-grade human transplant 
material, whereas autologous, cell-based treatments are clinically attractive. One emerging 
strategy is the use of mesenchymal stromal cells (MSCs) to take advantage of their anti-
inflammatory, immunoregulatory, angiogenic and regenerative properties. This Perspective 
will focus on the potential of MSC-derived soluble mediators to improve transplantation 
outcomes primarily by influencing graft function rather than affecting the host environment. 
 
Mesenchymal stromal cells  
The International Society for Cellular Therapy has designated the term ‘multipotent 
mesenchymal stromal cells’ (MSCs) to refer to cells often referred to previously as 
mesenchymal stem cells, which can be isolated from bone marrow and many other tissues 
including adipose, placenta, cord blood and the ocular limbus. To define cells as MSCs they 
must meet three main criteria13. First, cells must be plastic-adherent when maintained in 
standard culture conditions. Second, ≥ 95 % of cells must express CD105, CD73 and CD90, 
whilst they must lack hematopoietic antigen expression that includes CD45, CD34, CD14 or 
CD11b, CD79α or CD19 and HLA class II. Finally, MSCs must be capable of trilineage 
differentiation potential into osteoblasts, adipocytes and chondroblasts under the standard 
differentiation conditions in vitro. 
 
Mesenchymal stromal cells and islet transplantation  
MSCs are currently being investigated as adjuvants to improve the outcomes of islet 
transplantation. It is well established from studies in other tissues that MSCs play a major role 
in tissue repair by migrating to the site of injury and depositing extracellular matrix (ECM) 
which acts as a repair scaffold and as a reservoir for a wide range of MSC-derived biologically 
active molecules with anti-inflammatory, immumodulatory and angiogenic properties11-13, all 
of which might be predicted to enhance the functional survival of islet grafts. 
Studies in rodent models of diabetes have demonstrated that co-transplanting MSCs with 
islets improves the outcome of islet transplantation in terms of glycemic control 14–19. These 
beneficial effects have been attributed to the ability of MSCs to enhance revascularisation17,20 
or to suppress the host immune responses to the graft21–23. However, MSCs also improve 
transplantation outcomes of syngenic grafts17, which do not provoke an immune response, 
and in microencapsulated islet grafts18, which do not revascularise, suggesting that MSCs 
improve graft outomes via multiple mechanisms.  
 
Many of these in vivo islet transplantation studies use the renal subcapsular graft site because 
it is surgically accessible, it facilitates the anatomical co-localisation of islets and MSCs, and it 
enables surgical retrieval of the graft material (and thus reversion to hyperglycemia) by 
unilateral nephrectomy. However, clinical islet transplantation is almost exclusively via the 
hepatic portal vein, which does not facilitate co-engraftment of islets and MSCs. Thus, after 
intraportal delivery the islets (100-200 µm diameter) lodge in the hepatic microcirculation 
where they re-vascularise, while the much smaller MSCs (15-30 µm) pass through the liver 
and most likely end up in the lung microcirculation24. Attempts to co-localise islets and MSCs 
by generating islet:MSC composites have shown limited efficacy in vitro with no significant 
improvement in the in vivo transplantation outcomes in diabetic m𝑖𝑐𝑒46 . 
 
An alternative strategy to co-transplanting islets and MSCs is a pre-transplantation co-culture 
period in vitro to enhance islet functional survival before their subsequent engraftment, and 
several different configurations have been used to investigate the functional effects of co-
culture, as shown in Figure 1. Direct contact co-culture of islets with MSCs is consistently 
reported to improve glucose-stimulated insulin secretion (GSIS), whether configured as 
monolayer MSCs, or in suspension culture as composites25–28. However, discrepancies in the 
effect of MSCs on islet function have been observed in studies using indirect, non-contact co-
culture systems (Figure 1), with some reporting MSC-dependent improvements in GSIS17,29, 
and others reporting no effects 32-34. The efficacy of direct contact co-culture strategies may 
be due, at least in part, to the ability of MSCs to secrete abundant amounts of ECM30 which 
interacts with localised islet cells. Thus, elastin microfibril interface 1 (EMILIN-1) and integrin-
linked protein kinase (ILK-1) were reported to be highly expressed in MSCs populations with 
islet regenerative capabilities31, implicating ECM-integrin interactions in mediating the 
beneficial effects of MSCs on islet function. Consistent with this, MSCs which support islet 
function secrete protein matrix metalloproteases (MMP1 and MMP13) that are involved in 
ECM remodelling32, and co-culture of mouse and human islets with de-cellularized MSC-
derived ECM is alone sufficient to improve GSIS24.  
 
The ECM secreted by MSCs acts not only as a physical scaffold but also as a reservoir for 
numerous biologically active molecules to influence the function and regeneration of the 
surrounding tissues33. Mass spectrometry analysis of human bone marrow MSC-derived 
ECM33 has identified  a wide range of  secretory products, including  growth factors and anti-
inflammatory molecules, which reinforces the notion of MSC-derived ECM acting as a “mobile 
drug dispensary” for tissue regeneration. Indeed, many of the factors implicated in the 
beneficial effects on islets are associated with MSC-derived ECM33 (Table 1). This, in turn, 
raises the possibility of utilising MSC-derived molecules (see Table 1) to improve islet graft 
function without the requirement for delivering MSCs as part of the graft material. We have 
recently used a non-biased qRT-PCR strategy to screen MSC populations for the expression of 
peptide and protein ligands of G-protein-coupled receptors (GPCRs) known to be expressed 
by islet β-cells34. The anti-inflammatory molecule annexin A1 (ANXA1) was identified as a 
highly expressed secretory product in both mouse35 and human36 MSC populations, and has 
been localised to MSC-derived ECM36. Subsequent functional studies demonstrated that 
preculturing islets with exogenous ANXA1 improved GSIS in vitro24,26 , protected islet cells 
against cytokine-induced apoptosis35, and improved their ability to regulate glycaemia in 
diabetic mice35. However, ANXA1 is not the sole mechanism through which MSCs influence 
islet function since genetic deletion or siRNA-induced knockdown of ANXA1 in MSCs impaired, 
but did not completely abolish, their capacity to enhance islet function35. Two other 
molecules which are highly expressed by MSCs - stromal cell-derived factor1/C-X-C motif 
chemokine 12(SDF-1/CXCL12) and collagen type III alpha 1 (Col III A1) - are also reported to 
have beneficial effects on islet function37, and CXCL12 has been reported to enhance islet 
graft survival and function in a mouse model of diabetes38. This raises the possibility of 
defining a “cocktail” of MSC-derived molecules which mimics the beneficial effects of MSC co-
culture on islet function, and which therefore offers the prospect of cell-free treatment of 
islet populations during the isolation and pre-transplantation culture periods.   
 
Translation to clinical human islet transplantation protocols 
The use of a precisely-defined cocktail of MSC-derived products could overcome many of the 
technical hurdles of cellular therapy, such as upscaling MSC production whilst maintaining a 
stable phenotype, quality control between different MSC populations, the establishment of 
reliable safety and efficacy profiles, and the challenges of in vitro co-culture of MSCs and 
human islets on the scale required for clinical transplantation. MSC-derived products can be 
manufactured in GMP conditions, and evaluated for safety, dosage and potency in a manner 
similar to that applied to current pharmaceuticals. Indeed, several of these MSC 
biotherapeutic molecules and/or their receptors are currently under investigation for their 
therapeutic potential in other clinical situations39–41. 
 
A cell-free “cocktail” treatment of islets prior to transplantation may also offer regulatory 
advantages over cell-based adjuvant therapy. In the UK, human islets for clinical 
transplantation are covered by the Tissues and Cells Directive (2004/23/EC) and are 
considered as graft material rather than medicinal products by the Human Tissue Authority, 
so are exempt from the stringent regulations covering new medicinal products. If, as seems 
likely, pre-treating islets with MSC biotherapeutic molecules is maintaining their functional 
viability rather than inducing any fundamental modification they will continue to be classified 
as graft material rather than a medicinal product. Thus, for example, the biotherapeutic 
cocktail could be used as a supplement to the islet culture medium in an analagous manner 
to the inclusion of human serum albumin which is beneficial for islet survival since it 
neutralises endogenous pancreatic enzymes42. Translation of current experimental studies 
into modifications to clinical human islet transplantation protocols may therefore be 
relatively straightforward in regulatory terms. 
 
  
Summary and conclusions. 
There is a convincing body of experimental evidence demonstrating that MSCs can exert 
beneficial effects on the outcomes of islet transplantation as a therapy for T1D. Most likely 
through a number of different mechanisms involving MSC-derived molecules having direct 
effects on the islet graft to improve its functional survival, and on the host environment to 
suppress inflammatory and immune responses  to the graft. The MSC-dependent effects on 
the graft material may be mimicked, to some extent, by defined modifications to pre-
transplantation culture protocols, offering a simple and effective means of improving the 
cinical outcomes of islet transplantation. 
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Figure 1 Different co-culture systems for 
islets and MSCs.  
A) Direct contact co-culture system 45, where MSCs are 
seeded  in adherent monolayers in a treated tissue 
culture dish and islets are placed in direct contact on the 
layer of MSCs. B) Direct contact co-culture system 25, 
where MSCs are seeded in a non-treated culture and 
maintained in suspension culture with islets. C) Indirect 
co-culture system 17, in this system, MSCs are seeded 
as adherent monolayers  into the bottom of a transwell 
treated culture dish and islets are placed into the insert 
in the upper compartment of the well. 
C 
A 
B 
Table 1 Proposed mechanisms of action for MSCs to improve islet function 
Author/year MSCs Proposed  underlying mechanisms modulating islet 
functional viability 
Arzouni et al 201736 Human adipose-
derived MSCs 
Annexin A1 
MSC-derived extracellular matrix 
Lavoie et al 201631 Human bone 
marrow -derived 
MSCs 
EMILIN-1 
ILK-1  
Rackham et al 201635 Mouse adipose-
derived MSC 
Annexin A1 
 
Yamada et al 201429 Human adipose-
derived MSCs 
VEGF 
Bell et al 201232 Human umbilical 
cord blood/ Bone 
Marrow-derived 
MSCs 
Matrix metalloproteases (MMPs) 
Transforming growth factor-beta  (TGF-beta) 
Epidermal growth factor receptor (EGFR)-activating 
ligands  
Park et al 201017,43 Human umbilical 
cord blood-
derived MSCs 
Interleukin-6 (IL-6) 
Hepatocyte growth factor (HGF) 
TGF-beta 
Vascular endothelial growth factor-A  ( VEGF-A) 
 
Karaoz et al 201044 Rat bone 
marrow-derived 
MSCs 
IL-6 
TGF-beta1 
Fibronectin (FN) 
Phosphoprotein1 (SSP1) 
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